sábado, 7 de marzo de 2020

Licensing Opportunity: Monoclonal antibodies against Bacillus Anthracis antigens


Licensing Opportunity
Bacterial endospores from the Aimes strain of Bacillus anthracis bacteria. Credit: CDC/ Laura Rose
 Scanning electron microscopic (SEM) image of bacterial endospores from the Aimes strain of Bacillus anthracis bacteria. 
         Credit: CDC/ Laura Rose

Bacillus anthracis (B. anthracis) is the causative agent of anthrax. Scientists at NIAID have isolated several monoclonal antibodies (mAbs) against B. anthracis antigens from immunized chimpanzees.  These mAbs efficiently neutralized the toxicity in vitro and protected animals from the effects of anthrax toxin. The mAbs also showed strong killing of bacteria in vitro and protected mice experimentally challenged with B. anthracis. This technology has the potential to assist with prophylaxis, therapeutics or diagnostics against B. anthracis antigens.
Read more about this exciting opportunity at https://www.ott.nih.gov/technology/e-146-2004-0 or contact Jenish Patel, Ph.D., 240-669-2894; jenish.patel@nih.gov

No hay comentarios:

Publicar un comentario